Societal CDMO Inc

Societal CDMO, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Societal CDMO, Inc. is a bi-coastal CDMO with capabilities spanning pre-investigational new drug (IND) development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a focus on small molecules. With expertise in solving complex problems, the company provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill and finish, lyophilization, packaging, and logistics services to the pharmaceutical market. The company was founded in 2007. It has sites in Gainesville, GA, San Diego, CA, and is headquartered in Exton, PA.

CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. (“CoreRx”) today announced that it has completed its acquisition of Societal CDMO, Inc. (“Societal CDMO”) (Nasdaq: SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics.

CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Societal CDMO, Inc. (NasdaqCM: SCTL) to CoreRx, Inc. Under the terms of the proposed transaction, shareholders of Societal will receive $1.10 in cash for each share of Societal that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the cons.

SOCIETAL CDMO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Societal CDMO, Inc. - SCTL

Societal CDMO (NASDAQ: SCTL ) stock is rocketing higher on Thursday after the pharmaceutical development and manufacturing company announced an acquisition agreement with CoreRx. This agreement will have CoreRx acquiring Societal CDMO with a tender offer for SCTL shares.

Why Is Societal CDMO (SCTL) Stock Up 133% Today?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Societal CDMO, Inc. (NASDAQ: SCTL) to CoreRx, Inc. for $1.10 per share in cash is fair to Societal CDMO shareholders. Halper Sadeh encourages Societal CDMO shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Societ.

SCTL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Societal CDMO, Inc. Is Fair to Shareholders

Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging

Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreRx, Inc.

Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets

Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers

SAN DIEGO and GAINESVILLE, Ga., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the addition of new employees to fill open roles throughout the organization.

Societal CDMO Reports Inducement Grants for New Staff

Societal CDMO, Inc. (NASDAQ:SCTL ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Stephanie Diaz - Investor Relations Group David Enloe - President & Chief Executive Officer Ryan Lake - Chief Financial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Matt Hewitt - Craig-Hallum Capital Operator Good day, ladies and gentlemen, and welcome to the Societal CDMO Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Societal CDMO, Inc. (SCTL) Q3 2023 Earnings Call Transcript

Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corporate Restructuring; Expected to Result in Annualized Savings of Approximately $5.5 Million Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga.

Societal CDMO Reports Third Quarter 2023 Financial Results

Webcast Scheduled for Wednesday, November 8, 2023, at 4:30 p.m. Eastern Webcast Scheduled for Wednesday, November 8, 2023, at 4:30 p.m. Eastern

Societal CDMO to Report Financial Results for Third Quarter 2023 on November 8, 2023

SAN DIEGO and GAINESVILLE, Ga., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will participate at the RBC Capital Markets Virtual CDMO Conference. David Enloe, chief executive officer, will be the featured speaker in a fireside chat at the conference, which will take place October 2-3, 2023.

Societal CDMO to Participate in RBC Capital Markets Virtual CDMO Conference

Strategic Realignment Designed to Right Size Organization to Address Macro Pharma Market Financing Challenges and Increase Operational Efficiency in Areas of Historical Strength Strategic Realignment Designed to Right Size Organization to Address Macro Pharma Market Financing Challenges and Increase Operational Efficiency in Areas of Historical Strength

Societal CDMO Announces Corporate Restructuring

Additional Work Across Facilities in California and Georgia to Include Analytical Method Development and Validation, Dissolution Testing, and Manufacturing of Prototype, Surrogate, and Engineering Batches Additional Work Across Facilities in California and Georgia to Include Analytical Method Development and Validation, Dissolution Testing, and Manufacturing of Prototype, Surrogate, and Engineering Batches

Societal CDMO Secures Project Expansion Agreements With Several Existing Customers

SAN DIEGO and GAINESVILLE, Ga., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (“CDMO”) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company closed its previously announced underwritten public offering of 20,750,000 shares of its common stock (or common stock equivalents) at a public offering price of $0.40 per share of common stock (or common stock equivalent) on Monday, August 28, 2023. The gross proceeds of the offering were $8.3 million, before underwriting discounts and commissions and offering expenses. Societal intends to use the net proceeds from the offering for general corporate purposes.

Societal CDMO Announces Closing of $8.3 Million Public Offering of Common Stock

Societal CDMO stock dropped more than 33% at the open after the firm announced a discounted and dilutive equity raise for gross proceeds of $8.3 million. The contract development and manufacturing organization (CDMO) announced an offering of 20,750,000 shares at $0.40 per share, a steep discount to Wednesday's share price of about $0.60.

Societal CDMO stock drops on discounted offering

SAN DIEGO and GAINESVILLE, Ga., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (“CDMO”) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the pricing of its previously announced underwritten public offering of 20,750,000 shares of its common stock (or common stock equivalents) at a public offering price of $0.40 per share of common stock (or common stock equivalent), for gross proceeds of $8.3 million, before underwriting discounts and commissions and offering expenses. The offering is expected to close on or about August 28, 2023, subject to customary closing conditions.

Societal CDMO Announces Pricing of $8.3 Million Public Offering of Common Stock

Experienced Health Care Industry Investor with Track Record of Identifying Innovative Life Science Companies with High Growth Potential Experienced Health Care Industry Investor with Track Record of Identifying Innovative Life Science Companies with High Growth Potential

Societal CDMO Announces Appointment of Matt Arens to Board of Directors

SAN DIEGO and GAINESVILLE, Ga., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (“CDMO”) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). All of the shares of common stock (or common stock equivalents) are being offered by Societal. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Societal CDMO Announces Proposed Public Offering of Common Stock

Societal CDMO, Inc. (NASDAQ:SCTL ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Stephanie Diaz - Investor Relations Group David Enloe - President and Chief Executive Officer Ryan Lake - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Jacob Johnson - Stephens Max Smock - William Blair Thomas Keller - RBC Capital Markets Operator Good day, ladies and gentlemen, and welcome to the Societal CDMO Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Societal CDMO, Inc. (SCTL) Q2 2023 Earnings Call Transcript

Recorded Q2 Revenue of $21.8 Million Signed Multiple New Business Agreements with New and Existing Customers Secured Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement Agency; Allows Expansion into Manufacture of Psychedelic Drug Products Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga.

Societal CDMO Reports Second Quarter 2023 Financial Results

SAN DIEGO and GAINESVILLE, Ga., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced today that it has rescheduled its second quarter 2023 financial results reporting to Monday, August 14, 2023 at 4:30 p.m.

Societal CDMO Reschedules Second Quarter 2023 Financial Results Reporting to August 14, 2023

Webcast Scheduled for Wednesday, August 9, 2023, at 4:30 p.m. Eastern Webcast Scheduled for Wednesday, August 9, 2023, at 4:30 p.m. Eastern

Societal CDMO to Report Financial Results for Second Quarter 2023 on August 9, 2023

Company Secures Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement Agency, Expands on 25 Years of Manufacturing of Schedule 2 Products

Societal CDMO Announces Expansion of Controlled Substance Manufacturing Capabilities to Address Expanding Psychedelic Drug Development Market

Activities will be Conducted at Societal CDMO's San Diego Facility and Span Analytic Method Transfer, Process Development, and CGMP Manufacturing Activities will be Conducted at Societal CDMO's San Diego Facility and Span Analytic Method Transfer, Process Development, and CGMP Manufacturing

Societal CDMO Selected by Spinnaker Biosciences to Provide CDMO Services to Support Clinical Development of Novel Therapeutic Candidate

Scope of Work Spans Full Range of Services including Analytical Method Transfer, Formulation Development, Process Development, and Clinical Trial Material Batch Manufacturing Scope of Work Spans Full Range of Services including Analytical Method Transfer, Formulation Development, Process Development, and Clinical Trial Material Batch Manufacturing

News for Societal CDMO Inc Stock (SCTL)